The most common side effects in trials are gastrointestinal: nausea (around 43% at 12 mg), vomiting (21%), and diarrhoea (33%)
In a clinical trial with pediatric patients aged 10 years and older [see Clinical Studies (14.2)], anti-liraglutide antibodies were detected in 1 (2%) liraglutide injection-treated patient at week 26 and 5 (9%) liraglutide injection-treated patients at week 53
1 Introduction The gutbrain peptide, glucagon-like peptide-1 (GLP-1), is encoded by the proglucagon (PPG) gene, which is expressed in the intestines and pancreas [for a review, see PPG gene is also expressed in the olfactory bulb ( The extensive physiological and behavioral effects of GLP-1 are mediated by the GLP-1 receptors (GLP-1R), which are expressed in both the central and autonomic nervous systems ( Following ingestion of a meal, the GLP-1 levels rapidly increase
1 2 "Retatrutide-A Game Changer in Obesity Pharmacotherapy"
Retatrutide is a synthetic 39-amino acid acylated peptide designed as a triple agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR)
